We greatly value our faculty's scholarly contributions and are proud to honor their accomplishments.
Kevin Moriarty, MD, FACS
Kevin Moriarty, MD, Vice Chair for Academic Affairs and Professor of Surgery and Chief of Pediatric Surgery at UMMS-Baystate, received the Hampden County Community Clinician of the Year Award from the Hampden District Medical Society in April 2021. David Tashjian, MD, Medical Director of Pediatric Trauma at Baystate Medical Center, nominated Dr. Moriarty and described him as:
“…a true leader in the surgical care of children and in the education and mentorship of residents and faculty within the Division of Pediatric Surgery, Department of Surgery, and Baystate hospital system. He has long been a trusted partner and friend.”
The Clinician of the Year Award was established in 1998 to recognize a practitioner from each district medical society who has made significant contributions to patients and the community. The award is usually presented during the Medical Society’s spring meeting, but because of COVID-19, this year’s meeting was cancelled. Dr. Tashjian was proud to present the award virtually to Dr. Moriarty on April 15.
“I would like to say that I am humbled to be part of a great children’s surgical team and honored to be named the Hampden County Community Clinician of the Year,” said Dr. Moriarty. “I was born and raised in Hampden County and have been blessed to be able to practice medicine in my home community. The most rewarding [thing] to me is having helped a child, to see them laugh and their parents smile.”
Dr. Moriarty served as President of the Hampden District Medical Society from 2011-2012 and is currently a member of the Executive Board. He is also a member of the Executive Council and Board of Governors of the American College of Surgeons’ Massachusetts Chapter.
Nationally, Dr. Moriarty serves on the American Pediatric Surgical Association’s Practice Committee and is a member of the American Academy of Pediatrics’ Surgical Care Delivery Committee.
Dr. Moriarty noted, “I feel that it is also important to be at the table to advocate for your patients and the team both nationally and locally.”
We admire Dr. Moriarty’s numerous contributions to the surgical care of children in western Massachusetts. Congratulations!
Tashanna K.N. Myers, MD, FACOG, FACS
NRG Oncology, a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through international clinical research, recently appointed Tashanna Myers, MD of the Department of Obstetrics and Gynecology at University of Massachusetts Medical School-Baystate as an At-Large Director of the organization’s Board of Directors. This appointment was effective starting February 2021 for a 3-year renewable term.
Dr. Myers has an expansive background in gynecologic oncology research and clinical trials as well as a history in academics and education. She is currently the Site Principal Investigator for the following trials: the NCI COVID-19 in Cancer Patients Study (NCCAPS); the NRG-GY022 study on carboplatin clearance predictors; a Phase III trial for intermediate risk, stage I/IIA cervical cancer patients that have been previously treated with an initial radical hysterectomy and pelvic lymphadenectomy, or surgery to remove the lymph node; the NRG-GY019 trial for primary low grade serous ovarian cancer; the NRG-GY006 trial for women with newly bulky stage IB2, stage II, IIB, or IVA uterine cervix cancer or stage II-IVA vaginal cancer, and several industry supported trials.
In addition to her clinical research experience, Dr. Myers has held leadership positions including her current roles as Medical Director and Division Chief of the Department of Obstetrics and Gynecology at University of Massachusetts Medical School-Baystate and previous positions as Chair of the Diversity Committee at Baystate Medical Center. She has received several teaching honors from the Baystate OB/GYN Residency Program and Tufts University School of Medicine, and has been invited to speak at national presentations such as the Society for Gynecologic Oncology Annual Meeting.
“I look forward to utilizing my experiences and expertise to help this organization continue to contribute clinical meaningful research results and expand upon ways we can improve our current strategies and methods for the future,” stated Dr. Myers.
“In her new role, Dr. Myers will be a tremendous asset to the leadership of the NRG Oncology Board of Directors and helping NRG Oncology achieve their research goals and adhere to their mission,” added Robert S. Mannel, MD, an NRG Oncology Group Chair and the Director of the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center.